Evobrutinib did not beat Aubagio for MS flare-ups in trials
Key Takeaway
Evobrutinib did not reduce MS flare-ups more than Aubagio, and serious health problems were more common with evobrutinib.
What They Found
Two trials compared evobrutinib with teriflunomide (Aubagio) in adults with relapsing MS. Evobrutinib did not reduce flare-ups more than Aubagio in either trial. Health problems reported during treatment were similarly common in both groups. Serious health problems were more common with evobrutinib. Blood tests showed signs of possible liver damage more often with evobrutinib, especially early in treatment.
Who Should Care and Why
The trials studied adults with relapsing MS. Participants took either evobrutinib or Aubagio by mouth. The main question was whether evobrutinib prevented more flare-ups. The trials also compared health problems reported during treatment. The researchers concluded that the results did not support using evobrutinib for relapsing MS.
Important Considerations
You should know these were two trials with 2,290 people assigned to treatment. The trials did not show whether evobrutinib works better than treatments other than Aubagio. Health problems were reported during treatment, but the abstract does not say treatment caused every problem.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read More
10/9/2026
A mouse study suggests prepared red blood cells may calm MS-like immune attacks. Learn why liver cel
Read More
10/9/2026
See how lab-grown nerve cells move a key protein, why this may matter for nerve health, and why the
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like The Lancet. Neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.